Carlyle’s Global Credit platform and Arcmont Asset Management have announced a €470 million financing package for Bianalisi, an Italian healthcare diagnostics company. The deal, arranged with Natixis, aims to support Bianalisi’s expansion in the Italian market and refinance its existing debt.
Bianalisi operates across 13 regions in Italy, offering services in clinical laboratory diagnostics, outpatient care, and diagnostic imaging through a network of labs and facilities. CEO Giovanni Gianolli highlighted the importance of this financial support: “Thanks to this transaction, Bianalisi has secured substantial financial resources to continue its growth journey.”
Nicola Falcinelli from Carlyle expressed satisfaction with the partnership: “We are pleased to support Bianalisi to further expand its delivery of critical healthcare services.” Similarly, Vanni Mario Zanchi from Arcmont stated: “We are pleased to provide this significant backing for Bianalisi… We look forward to working closely with Giovanni and his team.”
Since receiving investment from Charme Capital Partners in 2021, Bianalisi has accelerated its growth through over 60 acquisitions. It serves more than 15,000 patients daily with a team of over 1,500 doctors and employees.
Carlyle is a global investment firm managing $441 billion in assets as of December 31, 2024. Its Global Credit platform manages $192 billion in assets. Arcmont Asset Management is part of Nuveen and provides capital solutions across Europe.
###
